STOCK TITAN
  1. Home
  2. Sec-filings
  3. CGTX
  4. [EFFECT] COGNITION THERAPEUTICS INC SEC Filing

[EFFECT] COGNITION THERAPEUTICS INC SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: December 23, 2025 4:00 P.M.
Form: S-3
CIK: 0001455365
Company Name: COGNITION THERAPEUTICS INC
File Number: 333-292240

Source: View Original Filing on SEC EDGAR

Stock CGTX logo
COGNITION THERAPEUTICS INC

NASDAQ:CGTX

CGTX Rankings

#5047 Ranked by Market Cap
N/A Ranked by Dividends

CGTX Latest News

Feb 5, 2026
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Jan 27, 2026
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
Jan 6, 2026
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
Dec 3, 2025
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Dec 1, 2025
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

CGTX Latest SEC Filings

Feb 5, 2026
[Form 4] COGNITION THERAPEUTICS INC Insider Trading Activity
Feb 5, 2026
[Form 4] COGNITION THERAPEUTICS INC Insider Trading Activity
Feb 5, 2026
[Form 4] COGNITION THERAPEUTICS INC Insider Trading Activity
Jan 27, 2026
[8-K] COGNITION THERAPEUTICS INC Reports Material Event
Dec 18, 2025
[8-K] COGNITION THERAPEUTICS INC Reports Material Event

CGTX Stock Data

98.87M
86.29M
0.7%
12.74%
10.43%
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
PURCHASE